MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination with lenalidomide, followed by Minjuvi® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not el ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024. The BLA is supported by positive data from the AGAVE-201 trial ...

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell.2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting task.Furthermore ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, deve ...

Incyte Corporation (INCY) reported fourth-quarter 2023 adjusted earnings of $1.06 per share, which missed the Zacks Consensus Estimate of $1.21. The company had recorded earnings of 62 cents per share in the year-ago quarter.Total revenues in the reported quarter were $1.01 billion, which grew 9.3% year over year, driven by the sustained performance of the lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) on strong launch and demand. The top line, however, marginally missed the ...

Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Conference Call February 13, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Hervé Hoppenot - Chief Executive Officer Barry Flannelly - General Manager, North America Pablo Cagnoni - President, Head of Research & Development Steven Stein - Chief Medical Officer Christiana Stamoulis - Chief Financial Officer Conference Call Participants Kripa Devarakonda - Truist Securities Andrew Berens - Leerink Michael Schmidt ...

Incyte (INCY) reported $1.01 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 9.4%. EPS of $1.06 for the same period compares to $0.62 a year ago.The reported revenue represents a surprise of -0.74% over the Zacks Consensus Estimate of $1.02 billion. With the consensus EPS estimate being $1.21, the EPS surprise was -12.40%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Incyte (INCY) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.40%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $1.09 per share when it actually produced earnings of $1.10, delivering a surprise of 0.92%.Over the last four quarters, the compa ...

| --- | --- | --- | --- | --- | --- | |------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | 2023 Fourth Quarter & Full-Year | | | | | | | Financial and Corporate Update February 13 th , 2024 | | | | | | Fourth Quarter & FY 2023 Earnings Call Agenda | --- | --- | |-----------------------|----------------------------------------------------------| | Introduction | Ben Strain \nHead of Investor Relations | | | | | Key Highli ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today reports 2023 fourth quarter financial results, provides 2024 financial guidance and provides a status update on the Company’s research and development portfolio. "We delivered a strong 2023 with total net product and royalty revenues of $3.7 billion, increasing 14% versus 2022. In the fourth quarter, we achieved for the first time, a new milestone of $1 billion in total quarterly revenues, driven by the continued growth of Jakafi® (ruxolitinib ...